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We appreciate the important thoughtful points raised
by Dr Heaf1 regarding adynamic bone disease (ABD).
ABD may indeed be a secondary phenomenon and a
consequence of the malnutrition–inflammation complex
syndrome (MICS), which is also associated with hypo-
albuminemia, increased serum levels of proinflammatory
cytokines, protein–energy wasting, and poor outcome in
maintenance dialysis patients.2 A recent study in 44
chronic peritoneal dialysis patients showed that low serum
albumin was associated with ABD.3 Although we are not
aware of any study that indicates a direct causal effect of
inflammation on ABD in chronic kidney disease, in vitro
parathyroid hormone (PTH) secretion is suppressed by
interleukin-6,4 a strong proinflammatory cytokine that is
associated with poor outcome in maintenance-dialysis
patients. Interleukin-1 beta (IL-1b), another proinflamma-
tory cytokine, may also suppress PTH secretion. In another
in vitro study, PTH secretion from cultured parathyroid
tissue slices was significantly inhibited in media containing
IL-1b.5 This effect may be mediated through the specific
IL-1 receptors that upregulate the calcium-sensing receptor
mRNA leading to apparent low bone turnover.5 Indeed in
the foregoing study, the inhibitory effect of IL-1b could be
counteracted by the IL-1 receptor antagonist (IL-1ra),5
indicating that the inflammation-induced suppression of
PTH can potentially be overcome by treatment of MICS in
individuals with chronic kidney disease. Hence, interven-
tions that can improve hypoalbuminemia and kidney
disease wasting by correcting malnutrition and/or by
mitigating inflammation, for example, via IL-1ra anakinra,
may be more promising approaches for the management of
ABD rather than decreasing the dose of or withholding
activated vitamin D analogs.
In our study, the MICS could indeed explain a large
portion of the association between low PTH and increased
death rate. However, in our epidemiologic study, inflam-
matory markers and cytokines were not measured. Hence,
controlling for MICS was suboptimal, which may explain
the existence of the residual association between low PTH
and death after multivariate adjustment. Moreover, many
patients with low PTH did not receive paricalcitol,6 which
may be another explanation for high mortality in this
group. Nevertheless, any dose of paricalcitol is associated
with better survival compared to no paricalcitol adminis-
tration, including in those with low PTH levels.6 As Dr
Heaf suggested, we plan to perform additional subgroup
analyses to examine more carefully the association of ABD
and MICS in maintenance-dialysis patients.
K Kalantar-Zadeh has received honoraria from Abbott
(manufacturer of calcitriol (calcijex) and paricalcitol
(zemplar)).
1. Heaf J. Adynamic bone disease and MICS. Kidney Int 2007; in press.
2. Kalantar-Zadeh K, Ikizler TA, Block G et al. Malnutrition–inflammation
complex syndrome in dialysis patients: causes and consequences. Am J
Kidney Dis 2003; 42: 864–881.
3. Sanchez-Gonzalez MC, Lopez-Barea F, Bajo MA et al. Serum albumin
levels, an additional factor implicated in hyperparathyroidism outcome in
peritoneal dialysis: a prospective study with paired bone biopsies. Adv
Perit Dial 2006; 22: 198–202.
4. Carlstedt E, Ridefelt P, Lind L et al. Interleukin-6 induced suppression
of bovine parathyroid hormone secretion. Biosci Rep 1999; 19:
35–42.
5. Nielsen PK, Rasmussen AK, Butters R et al. Inhibition of PTH secretion by
interleukin-1 beta in bovine parathyroid glands in vitro is associated with
an up-regulation of the calcium-sensing receptor mRNA. Biochem Biophys
Res Commun 1997; 238: 880–885.
6. Lee GH, Benner D, Regidor DL, Kalantar-Zadeh K. Impact of kidney bone
disease and its management on survival of patients on dialysis. J Ren
Nutri 2007; 17: 38–44.
K Kalantar-Zadeh1,2 and JD Kopple1,2,3
1Division of Nephrology and Hypertension, Los Angeles Biomedical Research
Institute at Harbor-UCLA Medical Center, Torrance, California, USA; 2David
Geffen School of Medicine at UCLA, Los Angeles, California, USA and
3UCLA School of Public Health, Los Angeles, California, USA
Correspondence: K Kalantar-Zadeh, Division of Nephrology and
Hypertension, Harbor-UCLA Medical Center, 1124 West Carson Street,
Torrance, California 90502. E-mail: kamkal@ucla.edu
Don’t be so BOLD: Potential
limitations in the use of BOLD MRI
for studies of renal oxygenation
Kidney International (2007) 71, 1327–1328; doi:10.1038/sj.ki.5002321
To the Editor: Blood oxygen level-dependent contrast
magnetic resonance imaging is used for studies of intrarenal
oxygenation1 and has been touted as a useful non-invasive
diagnostic tool in renal medicine. The validity of this
technique as an indicator of parenchymal oxygenation,
however, relies on the assumption that tissue oxygenation
varies with blood oxygenation. We recently found that in
both rabbits and rats renal cortical and medullary tissue pO2
can remain remarkably stable in the face of changes in renal
blood flow,2 even if renal oxygen consumption does not
change.3 We also observed increased renal venous blood
oxygen content with increasing renal blood flow, despite
stable tissue pO2.
3 These observations support the concept
that diffusional shunting of oxygen from arteries to veins
increases with increased renal blood flow and so contributes
to dynamic regulation of renal oxygenation.3 The possibility
that similar mechanisms operate in the human kidney raises
concerns over the reliability of clinical assessment of renal
tissue oxygenation using blood oxygen level-dependent
magnetic resonance imaging. Our data indicate that changes
in the oxygen level of blood in the renal circulation, as
evidence by altered renal venous pO2, do not necessarily
reflect changes in tissue pO2. The possibility that kidney
vascular oxygenation and tissue oxygenation may vary
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independently was suggested by Mason,1 and our recent data3
show that it actually occurs. We suggest that blood oxygen
level-dependent magnetic resonance imaging requires further
validation for use in estimating renal oxygenation. One
possible approach would be to use newer functional magnetic
resonance imaging techniques that employ extracellular pO2
reporter molecules.4
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It is indeed gratifying that our caveats and concerns have
been validated. We believe that the BOLD investigations
can be very useful, since they are noninvasive, using blood
as the reporter molecule. However, as the correspondents1
recognize there is interplay of oxygen delivery, consump-
tion, and clearance, and thus, assumptions are needed
when inferring changes in tissue pO2. Moreover, arterio-
venous (AV) shunting may separate tissue and capillary
phenomena from bulk AV measurements.
The correspondents cite their recent observations in rat
and rabbit kidney cortex and medulla on the basis of
polarographic electrodes, fluorescent fiber optic probes,
and arterial and venous blood samples.2 An MRI approach
could be even more powerful by interrogating multiple
locations simultaneously and providing quantitative pO2
based on reporter molecules, such as hexafluorobenzene3
or hexamethyldisiloxane.4 However, routine use in deep
organs, such as kidney, has been hindered by difficulty in
placing the exogenous reporter molecule, albeit using a
very fine needle. We certainly encourage such investiga-
tions. In the meantime, it would be interesting to apply
BOLD MRI to the models of Evans et al. The BOLD
measurements would be expected to be sensitive to
capillary oxygenation, which may or may not be associated
with bulk venous blood following major shunting. It could
also be valuable to apply both T1 and T2* measurements,
since these are attributable, respectively, to tissue5 and
vascular oxygenation.6
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by slowing of progression of
coronary calcification?
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To the Editor: We found the post hoc survival analysis of
Sevelamer in the incident hemodialysis patients thought
provoking.1 It is known from Dr Block’s original study that,
as compared to Calcium-containing binders, Sevelamer
slowed the progression of coronary artery calcification
(CAC) scores at 18 months.2 The current analysis shows
that mortality was predicted by phosphate binder use in the
first 18 months (lower mortality with Sevalamer) and by
‘baseline’ CAC score, but not by CAC score at 18 months.
This begs the question as to whether the slowing of
progression of CAC score using Sevelamer has any direct
effect on survival or is it possible that the survival benefit of
Sevelamer is independent of effects on calcification? Since the
patients underwent EBCT at regular intervals up to 18
months, the authors are in unique position to examine if
change (delta) in CAC score at 18 months had any direct
effect on survival.
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